These strategies included directly targeting sGC by sGC inhibitors and blocking downstream PKG activation by PKG inhibitors, and we have demonstrated the clinical potential of these inhibitor treatments in vitro and in vivo in TMPRSS2-ERG-positive PCa (see Figs. 5 and 6). This evidence concerns the gene PRKG1 and posterior cortical atrophy.